Christophe Douat - Medincell Chairman of the Management Board

MEDCL Stock  EUR 16.30  1.28  8.52%   

Insider

Christophe Douat is Chairman of the Management Board of Medincell SA
Age 57
Phone33 4 67 02 13 67
Webhttps://www.medincell.com

Medincell Management Efficiency

The company has return on total asset (ROA) of (0.3954) % which means that it has lost $0.3954 on every $100 spent on assets. This is way below average. Medincell's management efficiency ratios could be used to measure how well Medincell manages its routine affairs as well as how well it operates its assets and liabilities.
Medincell SA has accumulated 16.25 M in total debt with debt to equity ratio (D/E) of 4.61, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Medincell SA has a current ratio of 4.06, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Medincell until it has trouble settling it off, either with new capital or with free cash flow. So, Medincell's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Medincell SA sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Medincell to invest in growth at high rates of return. When we think about Medincell's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Regina JehleAbivax SA
N/A
Kader HidraHydrogen Refueling Solutions
N/A
Dominique MDOSE Pharma SA
68
TeylanBiophytis SA
N/A
Benoit CanolleBiophytis SA
45
Olivier DhezHydrogen Refueling Solutions
N/A
FFPM MBABiophytis SA
52
Hassen RachediHydrogen Refueling Solutions
N/A
Anne PascardAbivax SA
N/A
Brangre VasseurOSE Pharma SA
N/A
Prof EhrlichAbivax SA
N/A
Paul GinesteAbivax SA
N/A
Adamo ScrenciHydrogen Refueling Solutions
N/A
Alain MDOSE Pharma SA
N/A
Linda MScOSE Pharma SA
56
Pierre MBAAbivax SA
N/A
Francis EynardHydrogen Refueling Solutions
N/A
Philippe MDAbivax SA
65
JeanPascal PharmDOSE Pharma SA
N/A
Philippe RousseauBiophytis SA
52
Raquel LizarragaAbivax SA
N/A
It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients. Its product candidates in formulation research comprise subcutaneous injections, such as mdc-WWM for contraception mdc-ANG for CNS related treatments mdc-ELK for depression and mdc-GRT for use in organ transplant, as well as perineural injections, including mdc-CMV for anesthesia and pain, and mdc-NVA for pain. MEDINCELL is traded on Paris Stock Exchange in France. Medincell SA (MEDCL) is traded on Euronext Paris in France and employs 151 people.

Management Performance

Medincell SA Leadership Team

Elected by the shareholders, the Medincell's board of directors comprises two types of representatives: Medincell inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Medincell. The board's role is to monitor Medincell's management team and ensure that shareholders' interests are well served. Medincell's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Medincell's outside directors are responsible for providing unbiased perspectives on the board's policies.
Joel Richard, Member Board
Quiterie Beauregard, Head Portfolio
Helen Martin, Head Management
Julie Alimi, Head Legal
Sebastien Enault, Chief Officer
Christophe Douat, Chairman of the Management Board
Jaime Arango, Financial and Administrative Director
David Heuze, Head Board
Adolfo Noriega, Head Board
Franck Pouzache, Chief Officer

Medincell Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Medincell a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Medincell Stock Analysis

When running Medincell's price analysis, check to measure Medincell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medincell is operating at the current time. Most of Medincell's value examination focuses on studying past and present price action to predict the probability of Medincell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medincell's price. Additionally, you may evaluate how the addition of Medincell to your portfolios can decrease your overall portfolio volatility.